197 results on '"Thezenas S"'
Search Results
2. Radiothérapie stéréotaxique (RTST) pulmonaire des tumeurs de moins de 3 cm (stade I) et 5 cm (stade II) non opérées : 10 ans d’expérience de l’Institut du Cancer de Montpellier (ICM)
3. Résultats des reprises chirurgicales pour complications urétérales après transplantation rénale
4. Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?
5. A prospective phase II study evaluating the efficacy of oral immune modulating formulae on acute oral mucositis during radiochemotherapy in head and neck neoplasms
6. P14.04 Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases. A prospective study
7. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
8. Grossesse et tabac : pertinence d’un protocole de prise en charge du sevrage tabagique en consultation prénatale au CHU Arnaud-de-Villeneuve à Montpellier
9. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
10. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer
11. Impact de l’intégration d’uPA/PAI-1 et de l’invasion vasculo-lymphatique dans la prise en charge adjuvante des cancers du sein localisés
12. uPA-PAI-1 et paramètres clinicopathologiques classiques dans la prise en charge individualisée des cancers primaires du sein
13. Dosimetric Benefits of Stereotactic MR-guided Adaptive Radiotherapy in Locally Advanced Pancreatic Cancers
14. Involvement of CIP2A, a novel human oncoprotein inhibiting protein phosphatase 2A (PP2A), in breast cancer: YSF-62
15. Five-year change in statistical designs of phase II trials published in leading cancer journals
16. Étude de faisabilité de radiothérapie de conformation avec modulation d’intensité dans les cancers localisés de la prostate
17. Incidence et morbi-mortalité des tumeurs de la voie excrétrice du transplant après transplantation rénale : étude multicentrique française
18. Activités physiques adaptées et prise en charge nutritionnelle chez des patients présentant un cancer des Voies AéroDigestives Supérieures (VADS) traités à visée curative : résultats de l’essai de phase II randomisé contrôlé prospectif NUTRIMOUV
19. Quantifying circulating cell-free DNA as clinical biomarker
20. Évaluation sur données rétrospectives de la tolérance et de l’efficacité du dichlorure de radium-223 (Xofigo ® ) prescrit selon l’AMM (cancer de prostate)
21. Abstract P2-10-09: Clinical correlations of serum vitamin D in patients undergoing neoadjuvant systemic therapy and survival outcomes for operable breast cancer
22. Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
23. Neuroendocrine carcinoma of the uterine cervix: A retrospective monocentric study
24. Abstract P6-09-24: Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer
25. A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment
26. Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)
27. Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial
28. PO-0768: Evaluation of RT practice for limb soft tissue sarcomas and its impact on prognosis and toxicity
29. Abstract P6-17-03: Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
30. 159P - Quantifying circulating cell-free DNA as clinical biomarker
31. Évaluation sur données rétrospectives de la tolérance et de l’efficacité du dichlorure de radium-223 (Xofigo®) prescrit selon l’AMM (cancer de prostate)
32. Résultats à long terme de la radiothérapie conformationnelle avec modulation d’intensité des cancers du cavum
33. P-161 A phase I-trial assessing several schedules of Oral S-1 combined with fixed doses of Oxaliplatin and Irinotecan in patients with advanced or metastatic digestive adenocarcinoma as first- or second-line treatment
34. 529P - Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
35. 469P - Neuroendocrine carcinoma of the uterine cervix: A retrospective monocentric study
36. Volumetric Modulated Arc Therapy for Bilateral Breast Carcinoma: Dosimetric Analysis and Immediate Tolerance
37. EP-1323: Final results of the IMRT Montpellier pilot study for prostate cancer
38. 466PD - Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: a multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27)
39. 456O - Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial
40. SUN-LB280: Double Blind Multicenter Phase III Gortec Trial Evaluating the Efficacy of Oral Immune Modulating Formulae Therapy During Adjuvant Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)
41. Étude multicentrique en double insu de phase III réalisée avec le Gortec et évaluant l’efficacité d’une solution orale immunomodulatrice dans les cancers épidermoïdes de la tête et du cou
42. Combined Chemoradiation Therapy With Gemcitabine and Cisplatinum for Organ Preservation in Muscle-invasive Bladder Cancer: Long-term Results of a Phase I Trial
43. P4-17-09: Comparative Performances of Prognostic Indexes for Breast Cancer Patients Presenting with Brain Metastases.
44. P116 Impact d’une unité transversale de nutrition clinique sur la prescription de nutrition artificielle
45. P3-14-14: Increased Prevalence of Low Vitamin D Level in Breast Cancer Patients during Neoadjuvant Chemotherapy.
46. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
47. Facteurs pronostiques des métastases cérébrales dans le cancer du sein
48. 5098 POSTER Prognostic Factors of Breast Cancer Brain Metastases
49. 6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)
50. Abstract P2-06-04: Clinical Association of Invasion Factors UPA and PAI-1 and Classical Clinicopathological Parameters in Early Breast Cancer Patients: Implication for Individualized Therapy Decisions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.